PATIENT SQUARE CAPITAL LP
Q3 2026 Form 13-F

MENLO PARK, CALIFORNIA
CIK 0001819257 · CRD 312203 · SEC-registered investment adviser
$626.7M Reported Value Total

PATIENT SQUARE CAPITAL, LP reports 30 total accounts under management (AUM). There are 30 discretionary accounts valued at $17,512,552,081, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
32 funds · $17.2B gross asset value
Private Equity Fund: $17.2B
Source: Form ADV filed 2026-05-26
Reported value
$626.7M
Quarter over quarter
-0.8%
Holdings
23
Top-10 concentration
80.6%

Key People

Form ADV owners & control persons
James Cameron Momtazee
MANAGING MEMBER
Carolyn Joy Drayer-Greenwalt
CHIEF COMPLIANCE OFFICER AND MANAGING DIRECTOR
Adam Mark Fliss
FOUNDING PARTNER; HEAD OF STRATEGY, CAPITAL, LEGAL, AND GOVERNMENT AFFAIRS

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 10, 2026
Form 13F-HR
Reported value $626.7M
Positions 23
Change in reported value -2.9%
New positions 6
Exited positions 6
Position turnover 41.4%
Top-10 concentration 80.6%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 10, 2026
23 $626.7M
Q2 2026 13F
Filed Aug 12, 2026
23 $645.5M
Q1 2026 13F
Filed May 15, 2026
29 $563.6M
Q4 2025 13F
Filed Feb 12, 2026
28 $467.1M
Q3 2025 13F
Filed Nov 10, 2025
24 $373.9M
Q2 2025 13F
Filed Aug 11, 2025
19 $277.4M
Q1 2025 13F
Filed May 14, 2025
19 $241.7M
Q4 2024 13F
Filed Feb 14, 2025
20 $267.4M
Q3 2024 13F
Filed Nov 14, 2024
11 $269.4M
Q2 2024 13F
Filed Aug 13, 2024
2 $215.4M
Q1 2024 13F
Filed May 14, 2024
2 $234.8M
Q4 2023 13F
Filed Feb 13, 2024
2 $182.9M
Q3 2023 13F
Filed Nov 14, 2023
2 $182.0M
Q2 2023 13F
Filed Aug 11, 2023
2 $205.4M
Q1 2023 13F
Filed May 10, 2023
2 $124.4M
Q4 2022 13F
Filed Feb 13, 2023
2 $236.5M

Top 20 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 ROIV ROIVANT SCIENCES LTD $282.0M 45.0%
2 RVMD REVOLUTION MEDICINES INC $40.2M 6.42%
3 UTHR UNITED THERAPEUTICS CORP DEL $34.0M 5.42%
4 ARGX ARGENX SE $26.8M 4.28%
5 PHVS PHARVARIS N V $25.7M 4.09%
6 ABVX ABIVAX SA $24.1M 3.84%
7 BLTE BELITE BIO INC $22.4M 3.57%
8 MIRM MIRUM PHARMACEUTICALS INC $20.0M 3.19%
9 ZLAB ZAI LAB LTD $15.6M 2.49%
10 DFTX DEFINIUM THERAPEUTICS INC $14.7M 2.34%
11 CMPS COMPASS PATHWAYS PLC $13.1M 2.1%
12 DBVT DBV TECHNOLOGIES S A $13.0M 2.07%
13 ONC BEONE MEDICINES LTD $12.3M 1.96%
14 COGT COGENT BIOSCIENCES INC $11.6M 1.85%
15 RCUS ARCUS BIOSCIENCES INC $10.6M 1.69%
16 BNTX BIONTECH SE $10.4M 1.65%
17 ELVN ENLIVEN THERAPEUTICS INC $9.7M 1.55%
18 PCVX VAXCYTE INC $9.4M 1.51%
19 KYMR KYMERA THERAPEUTICS INC $9.4M 1.5%
20 ALLO ALLOGENE THERAPEUTICS INC $7.3M 1.16%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Similar Managers

Finding Similar Managers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings